The pharmaceutical market experienced robust growth in 2022, with a total valuation of $758,195 million. This reflects an impressive 8.71% increase compared to the previous year’s market value of $697,430 million. To gain insights into the market leaders based on revenue, an analysis of the top 30 pharmaceutical companies would be showcased as follows.
The revenue generated by leading pharmaceutical companies in 2022 can largely be attributed to the success of their blockbuster drugs. Notably, Comirnaty, the Covid-19 vaccine, and Humira, an anti-arthritis medication, hold the first and second positions, respectively. To visualize the revenue distribution, a treemap showcasing the top 50 drugs by revenue in 2022 is displayed below.
A few top-selling drugs in each pharmaceutical company typically contribute significantly to their overall revenue, and this holds especially true for Moderna. Spikevax, the Covid-19 vaccine developed by Moderna, has positioned the company ahead of long-established competitors like Vertex and Biogen. As the Covid-19 era fades, the longevity of Moderna’s position on the list becomes uncertain. To explore the revenue distribution among pharmaceutical companies, please refer to the interactive treemap provided via the link.
http://rubikschemistry.com/drug-sale-map-2022.html
